ADMA Biologics (ADMA) Reports In-Line Q2 EPS

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $60.13 million versus the consensus estimate of $55.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• HSBC sees more upside in Intel stock on server CPU opportunity
• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies